PharmaPendium(TM) Launches Pharmacokinetics Module

Provides Unprecedented Access to Detailed Drug Pharmacokinetics Data and Over 1,000,000 Extracted Exposure Observations From the FDA and EMEA Documents on More Than 2,100 Drugs

NEW YORK, September 14, 2010 - Elsevier today announces that it has significantly increased its service
offering to pharmaceutical R&D professionals with the launch of a new
Pharmacokinetics Module of PharmaPendium(TM), the online resource for
authoritative drug development data. The Pharmacokinetics Module allows
pharmacokineticists (and related professionals in regulatory affairs,
preclinical, safety pharmacology, etc.) to access multiple exposure parameter
measurements under various experimental conditions for over 2,100 drugs,
enabling the retrieval and analysis of over 1,000,000 pharmacokinetic
observations.

"The new Pharmacokinetics Module is not only a faster and more efficient
way to search pharmacokinetics data, it is the only place to find this level
of comparative exposure information, great for modeling and comparing
therapeutic windows earlier in the development process", said Philip
MacLaughlin, Senior Product Manager at Elsevier. "This is a level of
information that stands alone as a resource for Pharmacokinetics data, as it
can save months of work."

With the Pharmacokinetics Module, R&D professionals can model therapeutic
windows faster and more accurately than previously possible and discover
which preclinical experimental data is predictive of human response, which is
not, and why. Users will have the ability to filter comparative data sets for
decision support according to a wide variety of fields and special
designations, including drug name, species, disease state, food effects,
concomitant drugs, route, and exposure parameter.

The PharmaPendium(TM) module is available exclusively to existing
PharmaPendium(TM) customers. Purchase options include annual subscription or
data purchase (with annual maintenance fee).

About PharmaPendium(TM)

PharmaPendium(TM) (www.info.pharmapendium.com/), allows the user
to make informed drug development decisions. It is a unique online resource
that provides access via a single point to searchable and trusted drug
information. It covers close to 4,000 approved drugs, with integrated
preclinical, clinical and post-market safety data.

PharmaPendium(TM) is designed to meet the needs of preclinical safety
assessment teams, toxicologists, pharmacokineticists, safety pharmacologists,
regulatory affairs staff, pharmacoepidemiologists, clinical researchers, drug
discovery informatics and information specialists. It enables text-search of
FDA Approval Packages and European Medicines Agency (EMEA) European Public
Assessment Reports (EPAR) Approval Documents as well as other data sources.
Adverse events and toxicity data are carefully extracted from preclinical and
clinical studies from all of these sources. Elsevier offers a broad spectrum
of solutions to make processes in drug discovery, preclinical and clinical
drug development more efficient, e.g. Reaxys (www.info.reaxys.com),
Embase (www.info.embase.com) and PharmaPendium(TM) (
www.info.pharmapendium.com). PharmaPendium(TM) is owned and protected
by Elsevier Properties SA and used under license.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (www.thelancet.com) and Cell
(www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
ScienceDirect www.sciencedirect.com), Scopus (www.scopus.com),
Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and
Nursing Consult (www.nursingconsult.com), which enhance the
productivity of science and health professionals, and the SciVal suite
(www.scival.com) and MEDai's Pinpoint Review (www.medai.com),
which help research and health care institutions deliver better outcomes more
cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About Elsevier Properties SA

Elsevier Properties SA is a center of excellence within Reed Elsevier for
the management of intellectual property. Elsevier Properties SA owns the
PharmaPendium(TM), Beilstein and Reaxys databases. Trademarks including
Reaxys(R), PharmaPendium(TM) and The Lancet(R) are owned and protected by
Elsevier Properties SA and used under license. For additional information see
www.reedelsevier.com.

    Media Contact
    Tom Reller
    VP, Global Corporate Relations
    +1-215-239-3508
    T.Reller@elsevier.com

Media Contact: Tom Reller, VP, Global Corporate Relations, +1-215-239-3508, T.Reller at elsevier.com